deltatrials
Recruiting PHASE1 INTERVENTIONAL 6-arm NCT07237425

Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma

A Safety, Efficacy and Pharmacokinetic Evaluation Study of Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma

Sponsor: Glonova Pharma Co., Ltd

Conditions Lipoma Submental Fullness
Interventions Kybella Placebo Ronkyla Plus
Updated 2 times since 2025 Last updated: Nov 26, 2025 Started: Nov 14, 2025 Primary completion: Nov 14, 2026 Completion: Jan 14, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Lipoma and Submental Fullness and is currently actively recruiting participants. Glonova Pharma Co., Ltd leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshotRecruiting~Jan 2026 – present · 8 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1

  2. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glonova Pharma Co., Ltd
  • T-TOP Clinical Research Co., Ltd.
Data source: Glonova Pharma Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations